Patient disposition
| Disposition . | Primary study (N = 64) . | Extension study (N = 19) . |
|---|---|---|
| Idelalisib dose regimen, n (%) | ||
| 50 mg BID | 7 (11) | 0 |
| 150 mg QD | 9 (14) | 3 |
| 150 mg BID (3 wk on, 1 wk off) | 12 (19) | 1 |
| 100 mg BID | 7 (11) | 3 |
| 300 mg QD | 5 (8) | 3 |
| 150 mg BID | 10 (15) | 3 |
| 200 mg BID | 10 (15) | 4 |
| 350 mg BID | 4 (6) | 2 |
| Completed study (≥48 wk), n (%) | 19 (30) | 1 ongoing |
| Discontinued, n (%) | 45 (70) | 18 (95) |
| Disease progression | 23 (36) | 9 (47) |
| AE | 8 (13) | 4 (21) |
| Patient/investigator request | 2 (3) | 2 (11) |
| Withdrew consent | 2 (3) | 0 |
| Prohibited drug | 1 (2) | 0 |
| Patient noncompliance | 1 (2) | 0 |
| Death | 0 | 1 (5) |
| Other* | 8 (13) | 2 (11) |
| Disposition . | Primary study (N = 64) . | Extension study (N = 19) . |
|---|---|---|
| Idelalisib dose regimen, n (%) | ||
| 50 mg BID | 7 (11) | 0 |
| 150 mg QD | 9 (14) | 3 |
| 150 mg BID (3 wk on, 1 wk off) | 12 (19) | 1 |
| 100 mg BID | 7 (11) | 3 |
| 300 mg QD | 5 (8) | 3 |
| 150 mg BID | 10 (15) | 3 |
| 200 mg BID | 10 (15) | 4 |
| 350 mg BID | 4 (6) | 2 |
| Completed study (≥48 wk), n (%) | 19 (30) | 1 ongoing |
| Discontinued, n (%) | 45 (70) | 18 (95) |
| Disease progression | 23 (36) | 9 (47) |
| AE | 8 (13) | 4 (21) |
| Patient/investigator request | 2 (3) | 2 (11) |
| Withdrew consent | 2 (3) | 0 |
| Prohibited drug | 1 (2) | 0 |
| Patient noncompliance | 1 (2) | 0 |
| Death | 0 | 1 (5) |
| Other* | 8 (13) | 2 (11) |
Other in primary study includes: investigator decision/mild progression, need of additional therapy, deterioration of functional status, limited benefit; poor tolerance, patient decision/head injury; difficulty with transportation, and incarceration.